Breaking News Instant updates and real-time market news.

TSRO

Tesaro

$99.26

-0.63 (-0.63%)

08:08
10/10/16
10/10
08:08
10/10/16
08:08

TESARO price target raised to $120 at Raymond James

Raymond James analyst Christopher Raymond raised TESARO's price target to $120 from $105 fter the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Raymond thinks niraparib will have a broad ovarian cancer label and corresponding market opportunity and reiterates his Strong Buy rating.

  • 06

    Nov

  • 11

    Jan

TSRO Tesaro
$99.26

-0.63 (-0.63%)

10/10/16
BOFA
10/10/16
UPGRADE
Target $123
BOFA
Buy
TESARO upgraded to Buy following NOVA study data at BofA/Merrill
BofA/Merrill analyst Tazeen Ahmad upgraded TESARO to Buy and raised its price target to $123 from $97 after the company reported "clinically meaningful benefits in all the sub-populations" of the NOVA trial for niraparib. Ahmad said the data removes a key overhang of efficacy outside of BRCA mutations and sees a clearer path towards approval and a favorable label.
10/10/16
LTCO
10/10/16
DOWNGRADE
Target $16
LTCO
Sell
Myriad Genetics downgraded to Sell from Neutral at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter downgraded Myriad Genetics (MYGN) to Sell citing a "significant and unexpected deterioration" in outlook for the company's companion diagnostic franchise. The analyst expects a lower growth outlook to drive "significant P/E multiple compression." Tesaro (TSRO) presented data this weekend that suggested its PARP inhibitor niraparib was active in a maintenance setting for recurrent ovarian cancer in patients with either positive or negative HRD scores. The analyst had expected the drug to benefit only HRD positive patients. As such, the use of niraparib will not require HRD testing, DeGeeter tells investors in a research note. The analyst has a $16 price target for the shares.
10/10/16
PIPR
10/10/16
NO CHANGE
PIPR
Neutral
TESARO data suggest Myriad test not necessary, says Piper Jaffray
Piper Jaffray analyst William Quirk points out that data over the weekend from TESARO (TSRO), Myriad Genetics' (MYGN) companion diagnostic partner, suggest niraparib works in all-comers, making Myriad's test not necessary. Myriad shares may be down physiologically, Quirk tells investors in a research note partially titled "When A Partnership Produces Mixed Results." The analyst, however, believes niraparib is not clinically significant in HRD negative patients and that Myriad's test will be included on the drug label. He keeps a Neutral rating on shares of Myriad. Ladenburg Thalmann this morning downgraded the stock to Neutral.
10/10/16
LEER
10/10/16
NO CHANGE
Target $115
LEER
Outperform
TESARO price target raised to $115 after niraparib data at Leerink
Leerink analyst Seamus Fernandez said full results of TESARO's Phase 3 NOVA trial for niraparib as second-line maintenance for ovarian cancer presented at the ESMO meeting are strong enough to warrant approval in the overall patient population regardless of BRCAmut or HRD status. He increased his probability of approval in non-gBRCA/HRD-negative patients to 70% in the U.S., from 0%, and to 50% in the EU, from 0%. He raised his price target on TESARO shares to $115 from $108 per share and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

07:37
09/22/17
09/22
07:37
09/22/17
07:37
Conference/Events
Federal Reserve Bank of Kansas City President to speak at conference »

Kansas City Federal…

MYGN

Myriad Genetics

$33.61

0.1 (0.30%)

07:36
09/22/17
09/22
07:36
09/22/17
07:36
Recommendations
Myriad Genetics analyst commentary  »

Myriad Genetics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:35
09/22/17
09/22
07:35
09/22/17
07:35
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMD

AMD

$13.41

-0.33 (-2.40%)

, MSFT

Microsoft

$74.21

-0.73 (-0.97%)

07:35
09/22/17
09/22
07:35
09/22/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AMD

AMD

$13.41

-0.33 (-2.40%)

MSFT

Microsoft

$74.21

-0.73 (-0.97%)

INTC

Intel

$37.20

0.13 (0.35%)

ABBV

AbbVie

KMI

Kinder Morgan

$19.32

-0.45 (-2.28%)

GLNG

Golar LNG

$21.34

0.19 (0.90%)

HAS

Hasbro

$94.84

-0.68 (-0.71%)

MIK

Michaels

$21.38

-0.04 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 23

    Sep

  • 27

    Sep

  • 02

    Oct

  • 05

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:34
09/22/17
09/22
07:34
09/22/17
07:34
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AGRX

Agile Therapeutics

$3.77

0.04 (1.07%)

07:34
09/22/17
09/22
07:34
09/22/17
07:34
Initiation
Agile Therapeutics initiated  »

Agile Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Dec

SECO

Seeco Holding

07:33
09/22/17
09/22
07:33
09/22/17
07:33
Syndicate
Seeco Holding 8.5M share IPO priced at $13.00 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

AAXN

Axon

$22.80

-0.11 (-0.48%)

07:32
09/22/17
09/22
07:32
09/22/17
07:32
Hot Stocks
Axon receives multiple orders for TASER X26P, TASER X2 smart weapons »

Axon announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MU

Micron

$35.91

-0.06 (-0.17%)

07:32
09/22/17
09/22
07:32
09/22/17
07:32
Recommendations
Micron analyst commentary  »

Micron's November…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

FGP

Ferrellgas Partners LP

$5.02

-0.13 (-2.52%)

, MDU

MDU Resources

$26.21

-0.19 (-0.72%)

07:32
09/22/17
09/22
07:32
09/22/17
07:32
Hot Stocks
Ferrellgas Partners LP appoints Doran Schwartz as CFO »

Ferrellgas Partners L.P.…

FGP

Ferrellgas Partners LP

$5.02

-0.13 (-2.52%)

MDU

MDU Resources

$26.21

-0.19 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

FINL

Finish Line

$9.22

-0.21 (-2.23%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Technical Analysis
Technical View: Finish Line drops after earnings and outlook »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

PANW

Palo Alto Networks

$140.06

-1.69 (-1.19%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Conference/Events
Palo Alto Networks to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 07

    Dec

  • 11

    Dec

QCOM

Qualcomm

$52.03

0.05 (0.10%)

, NXPI

NXP Semiconductors

$112.72

0.17 (0.15%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Hot Stocks
Qualcomm extends cash tender offer for shares of NXP Semiconductors »

Qualcomm (QCOM) announced…

QCOM

Qualcomm

$52.03

0.05 (0.10%)

NXPI

NXP Semiconductors

$112.72

0.17 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

, TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Hot Stocks
Breaking Hot Stocks news story on Sprint, T-Mobile »

Sprint up 2.6% after…

S

Sprint

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

AZN

AstraZeneca

$32.81

-0.12 (-0.36%)

07:31
09/22/17
09/22
07:31
09/22/17
07:31
Upgrade
AstraZeneca rating change  »

AstraZeneca upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 08

    Nov

SXT

Sensient

$75.90

0.19 (0.25%)

07:30
09/22/17
09/22
07:30
09/22/17
07:30
Initiation
Sensient initiated  »

Sensient initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRVL

Marvell

, CAR

Avis Budget

$38.08

0.16 (0.42%)

07:30
09/22/17
09/22
07:30
09/22/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

MRVL

Marvell

CAR

Avis Budget

$38.08

0.16 (0.42%)

GIS

General Mills

$51.69

-0.48 (-0.92%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

HOG

Harley-Davidson

$47.96

-0.39 (-0.81%)

JBLU

JetBlue

$18.90

-0.35 (-1.82%)

MXWL

Maxwell

$4.97

-0.155 (-3.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 02

    Oct

  • 05

    Oct

  • 17

    Oct

  • 08

    Nov

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

, S

Sprint

07:29
09/22/17
09/22
07:29
09/22/17
07:29
Periodicals
T-Mobile, Sprint close to agreeing on deal terms, Reuters reports »

T-Mobile (TMUS) and…

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

S

Sprint

DTEGY

Deutsche Telekom

$18.36

-0.39 (-2.08%)

SFTBF

SoftBank

$81.50

-1.14 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

EADSY

Airbus

$23.07

0.78 (3.50%)

, BA

Boeing

$256.04

0.58 (0.23%)

07:29
09/22/17
09/22
07:29
09/22/17
07:29
Periodicals
Turkish Airlines mulls Airbus order following Boeing deal, Reuters reports »

Turkish Airlines has…

EADSY

Airbus

$23.07

0.78 (3.50%)

BA

Boeing

$256.04

0.58 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:28
09/22/17
09/22
07:28
09/22/17
07:28
Recommendations
Ascendis Pharma, Versartis analyst commentary  »

Ascendis Pharma price…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

07:28
09/22/17
09/22
07:28
09/22/17
07:28
Hot Stocks
Trump says greatest influence over election was 'Fake News Media' »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

, S

Sprint

07:27
09/22/17
09/22
07:27
09/22/17
07:27
Periodicals
Breaking Periodicals news story on T-Mobile, Sprint, Deutsche Telekom, SoftBank »

T-Mobile, Sprint close to…

TMUS

T-Mobile

$63.39

-0.13 (-0.20%)

S

Sprint

DTEGY

Deutsche Telekom

$18.36

-0.39 (-2.08%)

SFTBF

SoftBank

$81.50

-1.14 (-1.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 16

    May

FB

Facebook

$171.11

-1.06 (-0.62%)

07:26
09/22/17
09/22
07:26
09/22/17
07:26
Hot Stocks
Trump says Russia 'hoax' now onto Facebook ads »

President Donald Trump…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

07:25
09/22/17
09/22
07:25
09/22/17
07:25
General news
FX Update: »

FX Update: USD-JPY dove…

JNJ

Johnson & Johnson

$131.75

-1.47 (-1.10%)

07:24
09/22/17
09/22
07:24
09/22/17
07:24
Conference/Events
FDA PDUFA Date for Janssen Biotech, a Johnson & Johnson company, Sirukumab »

Janssen Biotech, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 26

    Sep

  • 27

    Sep

  • 17

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.